Cosmo pharmaceuticals
Ad Hoc Press Page

Ad Hoc Press Page

Cosmo has received approval of an extension in respect of the publication and the filing of its annual report 2023

Cosmo announces Leadership changes

Cosmo reports excellent preliminary unaudited Full Year 2023 core financial results – Record guidance for 2024 – Doubles dividend to € 2.00 per share

Cosmo Pharmaceuticals and Medtronic forge ahead in AI-driven care

Cosmo and Glenmark Announce the Signing of Distribution and License Agreements for Winlevi® in Europe and South Africa

Cosmo Presents Strong H1 2023 Operational and Financial Results

Cosmo Reports Record 2022 Financial Results Exceeding Guidance, Increased Dividend by 10%, Confirms 2023 Guidance

Cosmo Pharmaceuticals Announces that Cosmo Intelligent Medical Devices – IMD, Fully Owned Subsidiary of Cosmo Pharmaceuticals, and Medtronic to Expand Cooperation on GI Genius™

Cosmo Pharmaceuticals Reports Record Results for 2022, Preliminary Results Exceeding Guidance, Increased Dividend Distribution and 2023 Guidance

Cosmo and Hyphens Announce Signing of License and Supply Agreements for Winlevi® in Southeast Asia

Cosmo and Infectopharm Announce Signing of License and Distribution Agreement for Winlevi® in Germany, Italy and Austria

Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China

Cosmo Reports Strong Half-Year 2022 Financial Results Delivering Record Revenues and Reaffirms 2022 Full-Year Guidance

Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change

Cosmo Pharmaceuticals N.V. and Cassiopea S.p.A. Announce Settlement of Public Exchange Offer for All Publicly Held Shares in Cassiopea S.p.A.

Cosmo Pharmaceuticals N.V. and Cassiopea S.p.A. Publish Definitive Final Results of Public Exchange Offer for All Publicly Held Shares of Cassiopea S.p.A

Cosmo Pharmaceuticals N.V. and Cassiopea S.p.A. Publish Provisional Final Results of Public Exchange Offer for All Publicly Held Shares of Cassiopea S.p.A.

Cosmo Pharmaceuticals N.V. and Cassiopea S.p.A. Publish Definitive Interim Results of Public Exchange Offer for All Publicly Held Shares of Cassiopea S.p.A. and Declare the Offer Successful

Cosmo Announces Regulatory Approval of GI Genius™ in Canada

Cosmo Pharmaceuticals N.V. and Cassiopea S.p.A. Publish Provisional Interim Results of Public Exchange Offer for All Publicly Held Shares of Cassiopea S.p.A.

Interim Result of the Public Exchange Offer for All Publicly Held Shares of Cassiopea S.p.A.

Cosmo Pharmaceuticals N.V. Launches Public Exchange Offer to Acquire Cassiopea S.p.A.

Cosmo Pharmaceuticals N.V. Launches Public Exchange Offer to Acquire Cassiopea S.p.A.

Cosmo Half-Year Report 2021

Cosmo Pharmaceuticals Announces Cassiopea S.p.A.’s Signing of License and Supply Agreements for Winlevi® in US and Canada

Cosmo pharmaceuticals

Share price

2024© Cosmo Pharmaceuticals